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Although limited almost exclusively to military trainees, acute respiratory disease (ARD)
caused by adenovirus types 4 and 7 had been the leading cause ofhospitalization in U. S. Army
personnel. This disease which resembles influenza in clinical manifestations led to hospitaliza-
tion of as many as 50% of military trainees in midwinter and imposed a heavy burden on
military hospitals and training programs. In studies undertaken from 1965 to 1970, live
adenovirus type 4 and subsequently type 7 vaccines were found to be safe and immunogenic
and to confer protection against type specific adenovirus ARD. For the past 5 yr, military
trainees have been immunized with both adenovirus vaccines during periods of expected
adenovirus disease. Since 1966, use of adenovirus vaccines has been monitored through the
adenovirus surveillance program which yields weekly data on incidence and etiology ofARD in
basic combat trainees. Since 1973, stable adenovirus vaccines have resulted in excellent con-
trol ofadenovirus ARD. Potential problems with this immunization program are discussed.
Shortly after adenoviruses were first isolated from explant cultures ofhuman ade-
noid tissue by Rowe et al. (1), Hilleman and Werner of the Walter Reed Army
Institute of Research (WRAIR) (2) isolated a new strain of virus, subsequently
classified as adenovirus type 4 (Adv-4) from recruits at Ford Leonard Wood,
Missouri. It has since been amply confirmed that specific adenovirus serotypes-
principally types 4 and 7, and occasionally types 3, 11, 14, and 21-are important
causes of acute respiratory disease (ARD) in military trainees (3-6) although these
types cause but a small proportion of respiratory tract infections in civilian popula-
tions. While many aspects of the epidemiology of adenovirus ARD remain obscure
(7), the impact of this disease on military trainees and military training programs is
clear and is illustrated by the experience of a platoon of basic combat trainees
(BCTs) studied by our laboratory at Fort Dix, New Jersey, during the winter of
1965.
As previously described (8), these 48 men were followed by a WRAIR field team
from their arrival at the reception center at Fort Dix and throughout their training
were questioned and examined daily to detect symptoms of respiratory tract in-
fection. Daily temperatures were taken, and ifover 37.5° C, a more complete exami-
nation was made in order to document precisely signs and symptoms of ARD.
Twice a week the nasopharynx of each trainee was cultured for bacterial and viral
pathogens, while trainees with illness were sampled at onset ofillness and when hos-
pitalized. Disease was classified into afebrile, mild febrile, and severe febrile by cri-
teria based upon temperature (8). As shown in Table 1, 92 episodes of respiratory
illness were detected in the 8-wk training interval; 51 were afebrile, 17 mild febrile,
and 24 severe febrile. The 92 episodes resulted in 24 hospitalizations, ofwhich most,
but not all, came from trainees with severe febrile illness. The incidence of disease
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TABLE 1
Incidence and Clinical Severity of ARD in Platoon of Army Recruits
by Week of Basic Combat Training (BCT), Jan-Feb, 1965
No. men/wk BCT
Illness Total
0 1 2 3 4 5 6 7 8
Total strength 48 48 48 48 46 41 40 39 39
Afebrile URla 10 16 13 11 1 0 0 0 0 51
Mild febrile 0 6 3 3 2 1 0 1 1 17
Severe febrile 1 1 7 13 0 2 0 0 0 24
Total 11 23 23 27 3 3 0 1 1 92
Admitted to hospital 0 3 7 11 0 2 0 1 0 24
aURI-upper respiratory infection.
rose in the first 2 wk of training (Table 1) to peak in the second and third week of
training; this peak reflects that ofsevere febrile ARD and ofhospital admissions.
The etiology of afebrile disease (which did not result in any hospitalizations) was
not determined in 36 episodes but was associated with Adv-4 in the remaining 15 epi-
sodes. The etiology of febrile ARD, both mild and severe, was more commonly de-
termined. Adenovirus type 4 was associated with 19 of 24 episodes of severe febrile
ARD and 7 of 13 episodes of mild febrile ARD. Eighteen of the 24 trainees hospi-
talized had adenovirus type4 ARD.
Criteria for hospitalizing BCTs with ARD are, of course, less stringent than for
admission to a civilian hospital. Generally, U. S. Army Medical activities hospitalize
all febrile trainees with ARD symptoms. This policy was at least in part a response
to the necessity for close observation of febrile ARD patients for early signs of me-
ningococcal disease. On the other hand, most trainees hospitalized with adenovirus
ARD have fevers over 38.50 C associated with an illness remarkably similar to
influenza and are incapable of training. About 7-10% of those hospitalized have
radiologic evidence of pneumonitis and rare fatalities from adenoviral pneumonitis
in basic combat trainees have been reported (9, 10).
This Fort Dix study illustrates many of the characteristic features of ARD of
military trainees during the winter months. The majority of hospitalized or febrile
ARD patients have adenovirus infections. During the 8-wk training cycle, nearly
50% oftrainees are hospitalized with the majority ofhospitalizations in a unit occur-
ring within a 2-wk period. At northern BCT posts this translates to peak rates of6-
8/100 men/wk, or to 600-800 ARD admissions per week. At Fort Dix, four hospital
wards in Walson Army Hospital were devoted entirely to acute care offebrile ARD
patients. Also three to four wards ofthe hospital annex were opened and utilized for
convalescent care during the ARD season. Further, the loss of40% of the men of a
training company within a 2-wk period necessitated the establishment of an addi-
tional training program by the cadre to make up training lost as the result ofhospi-
talization. A significant proportion of trainees (nine in the platoon studied) were
"recycled" to other companies in an earlier stage of training, since their illness
placed them irretrievably behind their colleagues in the training cycle. Even at 1965
prices, the cost of hospitalization, of extra medical personnel required for ARD
wards, and oflost training time, washigh.
Initial attempts at control ofARD in recruits utilized inactivated adenovirus vac-
cines, initially bivalent (types 4 and 7) and later trivalent (with the addition of type
3). Although protection induced by pilot lots of these vaccines was promising
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initially, variation in antigenicity of vaccine lots became a significant problem. At
best, such vaccines effected a 70% reduction in type specific disease with an overall
mean reduction of 40% (8). In 1963 adenovirus seeds for these vaccines were found
to be contaminated with the oncogenic virus, SV-40, and the SV-40 genome was
found to be incorporated within adenovirus capsids. Consequently, immunization
with these vaccines was stopped and their license was rescinded.
Fortunately Couch and Chanock and colleagues at the National Institutes of
Allergy and Infectious Diseases were working on development of live adenovirus
vaccines. Making use of the observation that adenoviruses infect both the respira-
tory and gastrointestinal tract, but rarely produce gastrointestinal illness in adults,
these investigators tested the hypothesis that adenovirus could be given in enteric-
coated capsules to cause an asymptomatic infection of the gastrointestinal tract
without respiratory tract infection and that such infection would induce protection
against type specific respiratory tract disease. Preliminary experiments showed that
volunteers could be infected without illness upon ingestion of type 4 and 7 virus and
developed specific antibodies 2-3 wk after infection (11). When adenovirus type 4
vaccine was administered in an enteric-coated capsule to Marine recruit volunteers,
it produced a selective intestinal infection which was silent, noncommunicable, and
induced serum neutralizing antibodies (12). In 1964, with collaborating Naval
medical officers, Chanock demonstrated that the type 4 vaccine, administered to
Marine recruits at Parris Island, effectively reduced both hospitalizations for ARD
and Adv-4 infections which ordinarily occur in epidemics when recruits are trans-
ferred to Camp Lejeune for advanced training (13). Subsequently, in 1965, Buescher
and colleagues demonstrated that this vaccine was highly effective in Army trainees
at Fort Dix in a situation where trainees are naturally exposed to adenovirus infec-
tions within 7-10 days after arrival. In a study involving six companies, the Adv-4
vaccine reduced total ARD hospitalization by 67% and Adv-4 associated hospi-
talization by 95% (8).
A second trial at Fort Dix in early 1966 uncovered a serious problem with
monotypic adenovirus immunization (8). Beginning in February, all trainees in or
subsequently entering one of the two training brigades were immunized with live
Adv-4 vaccine, while trainees of the other brigade received placebo. Three weeks
after immunization, the ARD rates dropped precipitously in the immunized brigade
and remained low for 6 wk, when they increased sharply to rates of the unimmunized
brigade. This was due to the emergence of adenovirus type 7 in the immunized
brigade. While Adv-4 vaccine changed the infecting virus, the overall incidence of
ARD was unchanged. It was clear that a monotypic Adv-4 vaccine was not the final
answer to control of ARD in military trainees and would be useful only in posts with
Adv-4 ARD.
Before adenovirus vaccine could be administered rationally in the nine other BCT
posts, a system to monitor the incidence of ARD and the adenovirus serotype
etiology of hospitalized ARD was required. The Army Adenovirus Surveillance
Program, involving extensive collaboration between the Army area laboratories
under supervision of the Fort Baker, California, laboratory, the now Division of
Health and Environment, Office of the Su,rgeon General (OTSG), and the WRAIR,
was designed to assess variations in ARD prevalence and to provide contemporary
information about disease etiology to facilitate decisions as to when, where, and
what type of vaccines were needed to control recruit ARD. The mechanisms and
benefits of this surveillance program have recently been reviewed by Dudding et al.
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(14). Briefly, preventive medicine officers at each BCT post were required to submit
weekly reports to the OTSG, specifying (a) the number of trainees from each
training company, battalion, and brigade, admitted to the base hospital with an ad-
mission diagnosis of ARD (numerator), (b) the number of trainees in each of those
units (denominator), and (c) and ARD admission rate per 100 men per week for
each unit as well as for the entire BCT population on post, calculated from the
above. In addition, preventive medicine officers were required to provide throat
swabs and acute and convalescent sera for viral serology from a sample of recruits
hospitalized with ARD each week. The purpose was to determine what serotypes of
Adv were prevalent on various posts; therefore, specimens were collected
specifically from individuals most likely to have adenovirus disease (those with the
most severe symptoms and highest fevers who had been hospitalized less than 24 hr
previously). One-half the specimens from each post were sent to the Army medical
laboratory, Fort Baker, and the other halfto the regional Army medical laboratory.
These laboratories reported weekly the results of viral isolation and serologic
studies. This program proved ofgreat value in providing data necessary for rational
use oftype 4 and later type 7 vaccine in BCT populations.
During earlier development of adenovirus vaccines, it was discovered that certain
human adenoviruses were oncogenic for newborn hamsters and could transform rat
cells (15). Among these oncogenic types were types 3, 7, and 21; fortunately, type 4
has not been shown to be oncogenic, so that Adv-4 vaccine could continue to be used
in humans. Further studies of Adv-7 vaccines had to await results of studies of the
role of adenoviruses in human neoplasia. Certain characteristics of adenovirus in-
duced tumors in hamsters were exploited to determine the role of adenoviruses, if
any, in human tumors. First, in adenovirus-induced hamster tumors, the presence of
an early, nonstructural T antigen specific for adenovirusgroups could be detected by
complement fixation or fluorescent antibody techniques. Second, hamsters with tu-
mors developed serum antibodies to this T antigen. Third, messenger RNA specific
for adenovirus, could be detected in tumor cells by hybridization techniques with ra-
dioactive viral DNA. With the support of Solid Tumor Segment of the National
Cancer Institute, National Institutes of Health, Gilden and colleagues examined the
sera of 389 advanced solid tumor cases and controls for evidence of antibody to T
antigens of adenoviruses (16). No evidence of complement-fixing antibody to T an-
tigen ofknown oncogenic adenoviruses was found in cancer patients or control sera.
By the less specific FA technique, a small and similar prevalence of antibody to T
antigens was found in both groups. In a subsequent study, Green et al. (17) found no
evidence for virus-specific m-RNA in over 200 human cancer specimens examined.
These results suggested that adenoviruses are unlikely causes of tumors in man, but
if they are, the mechanisms involved are different from adenovirus carcinogenesis in
laboratory systems (which were the chief bases for suspecting their oncogenicity in
man in the first place). On the basis of these and many other studies, the National
Cancer Institute concluded that "adenoviruses ... were eliminated as causative
agents in human cancer" (18).
As a result of these studies, evaluation of live, adenovirus type 7 vaccines were
begun with the approval of the Vaccine Development Committee, NIAID, NIH,
and the Army Investigational Drug Review Board, Office ofthe Surgeon General. In
preliminary studies undertaken in military volunteers at the U. S. Army Medical
Research Institute of Infectious Diseases, Fort Detrick, Maryland, and the Army
Medical Training Center, Fort Sam Houston, Texas, the safety, infectivity, non-
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TABLE 2
Rates of Hospitalization due to Acute Respiratory Disease (ARD) in
Study Groups, Fort Dix, 1969
No. of men hospitalized (rate/100 men per 8 wk)
Group ARD due to adenovirus type ARD not due Total
4 7 to adenovirus
Test (231 men) 2(0.9) l(0.4)a 29(12.6) 32(13.9)b
Control (920 men) 8(0.9) 123(13.4) 109(11.8) 240(26.1)
Note. The test group received both adenovirus type 4 and adenovirus type 7 vaccines. The control
group received adenovirus type 4 vaccine and a placebo.
aX2 = 32.6, P < .0005.
bx2 = 15.3, P < .0005.
communicability, and immunogenicity of a live, enteric-coated type 7 vaccine was
established (19). It was also shown that the live Adv-7 and Adv-4 vaccines could be
given safely with no appreciable loss in infectivity or immunogenicity of either vac-
cine. In 1969, the protective effect of Adv-7 vaccine was evaluated in six companies
of trainees at Fort Dix during an outbreak of type 7 ARD. By random selection,
20% of trainees received both type 7 and type 4 vaccines, while 80% received a
placebo and type 4 vaccine (20). As shown in Table 2, the rate of ARD hospitaliza-
tion was significantly decreased in trainees receiving both vaccines. Adv-7 associated
ARD occurred 96% less frequently in the test group receiving the type 7 vaccine.
Rates for type 4 disease were low (0.9) and identical for both groups. Rates for ARD
not associated with adenoviral infection were similar for both groups, evidence that
immunization with type 7 vaccine did not mask detectability of type 7 infection in
previously immunized trainees.
A study of the impact of mass immunization with both adenovirus vaccines was
instituted at Fort Dix in 1970 (21). All recruits entering the 3rd training brigade
received both adenovirus vaccines within 72 hr of arrival on post, while those in the
2nd brigade (as in 1966) received only type 4 vaccine. All trainees reporting to Fort
Dix during a single week (one cohort) were formed into six training companies
TABLE 3
Total and Adenovirus-Associated ARD Hospitalization Rates
of Study Companies, Fort Dix, 1970
3rd Brigade
2nd Brigade (Adv-4) (Adv-4, Adv-7)
No. Ratea No. Ratea
Trainees 805 911
ARD hospitalizations Total 258 32.0e 149 16.3
Adv-7 associated 159 19.8b 9 1.0
Adv-4 associated 16 2.0c 49 5.4
Adv type undetermined 0 0.0 4 0.4
Total Adv associated 175 21.8d 62 6.8
Note: Trainees in the 2nd brigade received both adenovirus type 4 and 7 vaccines, while those in the
2nd brigade received only type 4 vaccine.
aRate/100/8 wk.
bChi square = 170.4, P < .001.
cChi square = 13.4, P < .001.
dChi square = 80.0, P < .001.
eChi square = 58.3,P< .001.
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assigned to one brigade; those reporting during the following week (another cohort)
formed six companies in the other brigade. All hospital ARD admissions in one of
the six companies constituting each of the ten weekly cohorts was studied for viral
etiology. ARD rates from study companies from the two brigades are detailed in
Table 3. Total ARD rates were 50% less in the 3rd brigade. This was due to a 95%
suppression in type 7 associated ARD in this brigade which received the type 7 vac-
cine. There was a small but significant increase in the incidence oftype 4 associated
disease in this brigade. This was evidence of some interference of the type 7 vaccine
with protective efficacy of the type 4 vaccine, and may have been due in part to the
relatively low potency of the type 4 vaccine used in this study. Despite this, total
adenovirus-associated disease was reduced by two-thirds in the brigade receiving the
bivalent vaccine. No significant difference in rates of ARD not associated with
adenoviruses was seen between the 2nd brigade (10.2/100) and the 3rd brigade (9.5/
100). No other respiratory pathogens emerged to replace Adv-4 and 7 as major
causes ofARD in this immunized population (22).
At this point it seems desirable to consider how adenovirus vaccines may protect
against respiratory tract disease. While serum, as well as local secretory respiratory
tract antibodies, are induced by natural adenovirus infection (23), intestinal infection
with vaccine virus induces serum and intestinal antibody, but does not induce anti-
body in the respiratory tract (24, 25). It is remarkable that a vaccine which induces
serum neutralizing antibody alone protects against adenovirus respiratory disease.
Respiratory tract infection with vaccine virus is readily induced in volunteers im-
munized with adenovirus vaccines, but uncommonly induced in volunteers with pre-
vious evidence of specific adenovirus infection (24). Further, respiratory tract in-
fection with homologous adenovirus is not uncommon in military trainees studied
sequentially after adenovirus type 4 immunization, but rarely results in hospitaliza-
tion (Top, F. H., Jr., unpublished observations). Although studies to quantitate the
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FIG. 1. Acute respiratory disease rates in basic combat trainees at Fort Leonard Wood, Missouri,
1966-1974. The bars at the bottom of the graph indicate vaccination periods with the respective vaccine
titers as noted.
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effect of adenovirus vaccines on naturally occurring infection in military trainees
have not been undertaken, these vaccines do not totally prevent subsequent respira-
tory tract infection by homologous adenovirus type.
Since 1971, both adenovirus vaccines have been used at U. S. Army BCT posts
during periods of anticipated adenovirus ARD. Schedules of immunization have
been tailored to individual posts with the objective being control, rather than
eradication, of adenovirus ARD. From 1971 to 1973, control was less than optimal,
primarily due to virus stability problems with many vaccine lots. The 2-3 log
decrease in virus titer within months after manufacture was traced to contamination
of the vaccine virus in the core of the tablet by solvent used in the enteric coating
process (Bernstein, A., personal communication). Adequate ventilation of solvent
during this process through new drying equipment has produced stable vaccines
since January 1974. Problems engendered by monovalent immunization alone or by
vaccines of low potency are shown in the next three figures. Figure 1 portrays ARD
experience at Fort Leonard Wood since 1966 when adenovirus surveillance began. In
1967 and 1969, the use of type 4 vaccine led to the emergence of Adv-7 within 2 mo
after beginning immunization. As in Forts Jackson and Dix (Figs. 2 and 3), Adv-7
persisted on post after cessation of type 4 immunization through the subsequent
ARD season; only about 2 yr after use of Adv-4 vaccine could Adv-4 vaccine again
be used to control ARD at these posts. At Fort Wood both adenovirus vaccines
were used beginning in the middle of February 1970, and this resulted in a precipi-
tous decline in ARD rates. A type 4 vaccine of low potency used in the fall of 1971
led to an Adv-4 outbreak, and an unstable type 7 vaccine used from January 1972
through January 1973 resulted in a sustained outbreak of Adv-7 ARD. Since the use
of stable type 7 vaccines beginning in January 1973, outbreaks of adenovirus ARD
at Fort Wood have not occurred. Increased ARD rates from January through May
1974 were due to influenza B and rubella; less than 5% ofill trainees had adenovirus
infections during those months.
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FIG. 2. Acute respiratory disease rates in basic combat trainees at Fort Jackson, South Carolina,
1966-1974. Legend same as for Fig. 1.
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FORT DIX, N.J.
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FIG. 3. Acute respiratory disease rates in basic combat trainees
at Fort Dix, New Jersey, 1966-1974.
Legend same as for Fig. 1.
At Fort Jackson (Fig. 2) the pattern was qualitatively similar but quantitatively less severe than at Fort Wood. Again, unstable type 7 vaccines used in 1972 led to Adven outbreaks (which persisted during the summer months, as at Fort Wood). Since January 1973, ARD rates have rarely exceeded 1.0/100/wk and few
adenoviruses have been isolated from trainees with ARD.
ARD patterns are more impressive at Fort Dix (Fig. 3) where, despite similar
problems with type 7 vaccines, ARD rates rarely exceeded the 3.0/1l00/wk expected
even during the summer months at Dix prior to 1970. Since January 1973, the rate
exceeded 2.0/100/wk in only 1 mo, and adenovirus has been isolated from less than
5% of trainees hospitalized at Walson Army Hospital, a far cry from previous
experience there. Vaccines in current use are potent and their use in the six BCT
posts during fall 1974 has resulted in blunting of early type 4 epidemics at Forts
Knox and Dix. We hope that the last 2 yr experience with potent adenovirus vaccines
will prove the rule rather than theexizeption.
Because of the large number of recruit hospitalizations for ARD, even a modest
reduction in disease results in significant savings. Collis et al. (26) undertook a cost
benefit analysis ofthe entire adenovirus surveillance program. Heestimated that be-
tween 1966 and 1971, the total cost of the surveillance program, including vaccine
development, vaccine purchases, administration, and laboratory support was $4.83
million. Using his estimate ofroughly 27,000 Army ARD hospitalizations prevented
during the 2 yr 1970 and 1971 at an average cost of $279 per hospitalization, the
dollar estimates of benefits derived from vaccine use was $7.53 million. Thus
benefits derived in the 2-yr period of bivalent vaccine use outweighed the total costs
ofthe program over a 5-yr period.
Although rates have been low and training and hospital commanders reasonably
happy with ARD control for the past 2 yr, there are potential problems which could
affect this program.
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Although adenoviruses other than types 4 and 7 have not been encountered in
Army trainees since type 21 appeared at Fort Dix in 1967 (27), ARD caused by
adenoviruses other than types 4 and 7 remains a frightening possibility. Although
their absence may reflect a limited or sporadic possibility of introduction into BCT
posts, the critical question of their transmissibility once introduced in the absence of
simultaneous transmission ofeither types 4 or 7 is unanswered. Approximately 85%
of Army trainees lack neutralizing antibody to Adv 21 (Top, F. H., Jr., unpublished
observation), and this virus has caused significant ARD outbreaks in Dutch (5),
Russian (28), Indian (29), and U. S. troops (27). A type 21 vaccine was found similar
to types 4 and 7 in regard to safety, infectivity and immunogenicity in
military volunteers in studies by our group (30), but the protective efficacy of the
vaccine has not been tested.
Primary human embryonic kidney cell (HEK)cultures are far more sensitive and
convenient than other cells (31) for adenovirus isolation and have been used in the
adenovirus surveillance system since its inception. The effect ofproposed legislation
dealing with medical experiments involving human fetuses upon the availability of
HEK cells (as well as other cell lines such as human diploid fibroblast cells used for
vaccine production) is not clear at time ofwriting.
A third problem is remaining uncertainty as to the role ofadenoviruses in human
tumors. Previous studies, reviewed above, could not incriminate adenoviruses as a
cause of human tumors. Although the techniques used to detect adenovirus specific
proteins or m-RNA in these studies were sufficiently sensitive to establish the
adenovirus etiology of tumors in hamsters, it is possible that they were not
sufficiently sensitive to detect adenovirus fingerprints in human tumors. In view of
the latency of certain adenoviruses (especially types 1, 2, 5, and 6) in human tissue
(32), it would be surprising ifthe genome ofcertain adenovirus types could not be de-
tected in humans. Currently the U. S. Army Medical Research and Development
Command, together with the Bureau of Biologics, Food and Drug Administration,
and the National Institutes of Allergy and Infectious Diseases, National Institutes
of Health, is funding a study to determine the prevalence of adenovirus genome in
tissues from patients with and without neoplasia, using a DNA hybridization tech-
nique which is 10-100 times more sensitive than the methods used to detect
adenovirus m-RNA in previous studies. The results of the study are awaited with
considerable interest.
In summary, adenovirus ARD has been the major cause of morbidity in military
trainees and the leading cause ofmilitary hospitalizations in the United States. Cur-
rently this disease is well controlled by immunization with live, oral, enteric-coated
adenovirus types 4 and 7 vaccines. It should be evident from this review that the suc-
cess of this program has resulted from the combined efforts of many interested
investigators, both civilian and military. Further experience is required to determine
the ultimate impact of adenovirus types 11, 14, and 21 in trainees immunized with
types 4 and 7 vaccines, and more sensitive studies of the role of adenoviruses in
human neoplasia are required and are in progress.
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